News | November 29, 2022
CPhI and P-MEC India sees participation of over 1500 exhibitors
40,000 visitors and representatives of more than 80 countries set to visit the show
40,000 visitors and representatives of more than 80 countries set to visit the show
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
The product is expected to be launched by Q4 FY23.
The plant at Raleigh, North Carolina, USA owned by Aurolife Pharma has received an establishment inspection report (EIR)
The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA
The approved product has an estimated market size of around US$ 606 million for the twelve months ending June 2022, according to IQVIA.
This is the 142nd ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.
he approved product has an estimated market size of US$ 83 million for the twelve months ending April 2022, according to IQVIA.
The Innopack confex is a perfect platform for exhibitors to demonstrate their latest developments in the fields of pharmaceutical packaging, labelling, drug delivery device design and engineering.
Pemetrexed for injection is indicated for the treatment of Antineoplastics (medications used to treat cancer)
Subscribe To Our Newsletter & Stay Updated
